Fundraising FoxMedicxi — 2017 Investments
2 investments dated 2017 · listed companies and verified rows first · show all
Diasomediasome.cominJul 2017 · $30M
Diasome develops metabolic therapies using its HDV platform to enable targeted drug delivery for treating diabetes, obesity, and metabolic diseases.
BiotechHealthtechMedical Devices
Robert Geho(Co-Founder, Chief Executive Officer)inW. Blair Geho(Co-Founder, Chief Scientific Officer)in
Co-investorsJDRF T1D Fund
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.